Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Bicara Therapeutics Inc. (NASDAQ:BCAX) has earned a consensus rating of “Moderate Buy” from the eight brokerages that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, five have given a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $31.8586.

Several analysts have recently issued reports on the company. Piper Sandler assumed coverage on Bicara Therapeutics in a report on Monday, August 18th. They set an “overweight” rating and a $36.00 target price on the stock. HC Wainwright reduced their target price on Bicara Therapeutics from $41.00 to $40.00 and set a “buy” rating on the stock in a report on Friday, August 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Bicara Therapeutics in a report on Tuesday, October 14th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $30.00 price objective on shares of Bicara Therapeutics in a research note on Tuesday, August 12th.

Bicara Therapeutics Stock Performance

BCAX opened at $17.06 on Wednesday. The firm has a market cap of $931.65 million and a P/E ratio of -5.38. Bicara Therapeutics has a 52-week low of $7.80 and a 52-week high of $28.09. The business’s fifty day moving average is $13.53 and its 200-day moving average is $12.11.

Bicara Therapeutics (NASDAQ:BCAX) last released its earnings results on Tuesday, August 12th. The company reported ($0.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.04. On average, research analysts predict that Bicara Therapeutics will post -2.59 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Bicara Therapeutics news, insider David Raben sold 22,000 shares of the business’s stock in a transaction dated Thursday, October 9th. The stock was sold at an average price of $18.45, for a total transaction of $405,900.00. Following the completion of the transaction, the insider owned 35,497 shares of the company’s stock, valued at approximately $654,919.65. The trade was a 38.26% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Ryan Cohlhepp sold 39,600 shares of the business’s stock in a transaction dated Monday, October 6th. The stock was sold at an average price of $18.06, for a total value of $715,176.00. Following the transaction, the chief operating officer directly owned 205,541 shares of the company’s stock, valued at approximately $3,712,070.46. The trade was a 16.15% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 146,534 shares of company stock worth $2,682,012 in the last ninety days.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of BCAX. Vestal Point Capital LP raised its stake in Bicara Therapeutics by 80.6% during the second quarter. Vestal Point Capital LP now owns 5,000,000 shares of the company’s stock worth $46,450,000 after acquiring an additional 2,231,025 shares in the last quarter. Wellington Management Group LLP raised its position in Bicara Therapeutics by 84.0% in the first quarter. Wellington Management Group LLP now owns 1,394,676 shares of the company’s stock valued at $18,173,000 after purchasing an additional 636,708 shares during the last quarter. Bank of America Corp DE raised its position in Bicara Therapeutics by 2,351.0% in the second quarter. Bank of America Corp DE now owns 451,228 shares of the company’s stock valued at $4,192,000 after purchasing an additional 432,818 shares during the last quarter. Artisan Partners Limited Partnership bought a new position in Bicara Therapeutics in the second quarter valued at about $3,742,000. Finally, Schroder Investment Management Group raised its position in Bicara Therapeutics by 921.0% in the second quarter. Schroder Investment Management Group now owns 425,341 shares of the company’s stock valued at $3,951,000 after purchasing an additional 383,681 shares during the last quarter.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.